US 11,724,991 B1
Selective 5-LO inhibitors for the treatment of bronchial asthma
Saadeldin Elsayed Ibrahim Shabaan, Al-Ahsa (SA); and Hany Mohamed Abd El-Lateef Ahmed, Al-Ahsa (SA)
Assigned to KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed by KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed on Jan. 6, 2023, as Appl. No. 18/94,113.
Int. Cl. C07D 257/04 (2006.01); C07D 403/10 (2006.01)
CPC C07D 257/04 (2013.01) [C07D 403/10 (2013.01)] 16 Claims
 
1. A compound having the formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein
X is O or NR6, wherein R6 is acetyl;
R1 and R2 are independently hydrogen, straight or branched C1-C6 alkyl, or straight or branched C2-C6 alkenyl, or wherein R1 and R2 can be taken together, along with the carbon atoms to which they are attached, to form a phenyl ring;
R3 is hydrogen, straight or branched C1-C6 alkyl, or straight or branched C2-C6 alkenyl; and
R4 and R5 are independently hydrogen, straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, or are taken together to form a C1 alkenyl, wherein said straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, or C1 alkenyl is unsubstituted or can be substituted with one or more substituents independently selected from the group consisting of an unsubstituted phenyl ring, a substituted phenyl ring, an unsubstituted tetrazole ring, or a substituted tetrazole ring, or wherein R4 and R5 can be taken together, along with the nitrogen atom to which they are attached, to form a maleimide group.